Molecular Weight(MW): 464.44
Crenigacestat (LY3039478) is an oral Notch inhibitor with an IC50 of 0.41 nM.
1 Customer Review
Effect of LY3039478 on Hes protein in SGC7901/DDP cells. A, Protein expression of Hes-1 by Western blot. B, Expression level of Hes-1 by Western blot experiment. (*p < 0.05 control with LY3039478 0 μmol/L group; **p < 0.01 control with LY3039478 0 μmol/L group).
Eur Rev Med Pharmacol Sci, 2018, 22(13):4121-4127. Crenigacestat (LY3039478) purchased from Selleck.
Purity & Quality Control
Choose Selective Gamma-secretase Inhibitors
|Description||Crenigacestat (LY3039478) is an oral Notch inhibitor with an IC50 of 0.41 nM.|
LY3039478 is a novel small molecule that is an exquisitely potent inhibitor of Notch-1 intracellular domain (N1ICD) cleavage with an IC50 of ∼1nM in most of the tumor cell lines tested. LY3039478 also potently inhibits mutant Notch receptor activity. Treatment with a gamma secretase inhibitor, LY3039478, significantly inhibited the growth of 2 CCRCC(Clear cell renal cell carcinoma) cell lines in a concentration dependent manner. LY3039478 treatment also led to decreased expression of Myc and Cyclin A1, two genes that were part of the NOTCH driven proliferative signature in murine and human model systems. LY3039478 treatment also led to G0/G1 cell cycle arrest in CCRCC cells.
|In vivo||In mice, its oral bioavalability(%F) is 65%, clearance(CL)=41 mL/min/kg, VDss = 3.8 L/kg. In Rats, its oral bioavalability(%F) is 65%, CL=98 mL/min/kg, VDss=4.9 L/kg. In Dogs, its oral bioavalability (%F) is 67%, CL=3.8 mL/min/kg, VDss=1.4 L/kg. In a xenograft tumor model, LY3039478 inhibited N1ICD cleavage and expression of Notch-regulated genes in the tumor microenvironment. The inhibition of Notch cleavage also resulted in the induction of apoptosis in a Notch-dependent xenograft model. In immunodeficient NSG mice xenografted with 769-P CCRCC cells, LY3039478 treatment resulted in significantly increased survival and delayed tumor growth in independent cohorts of mice demonstrating in vivo efficacy in CCRCC.|
-  Eli Lilly Company. The 8th SCI-RSC Symposium on Proteinase Inhibitor Design. 2013.
-  Mark H. Bender, et al. Cancer Res, 2013, 73(8 Suppl):Abstract nr 1131.
-  Bhagat TD, et al. J Biol Chem. 2017, 292(3):837-846.
|In vitro||DMSO||92 mg/mL (198.08 mM)|
|Ethanol||71 mg/mL (152.87 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT03502577||Recruiting||Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma||Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)||May 23 2018||Phase 1|
|NCT02784795||Active not recruiting||Solid Tumor|Breast Cancer|Colon Cancer|Cholangiocarcinoma|Soft Tissue Sarcoma||Eli Lilly and Company||November 4 2016||Phase 1|
|NCT02906618||Completed||Healthy||Eli Lilly and Company||October 4 2016||Phase 1|
|NCT02917733||Completed||Healthy||Eli Lilly and Company||September 2016||Phase 1|
|NCT02836600||Active not recruiting||Advanced Solid Tumor||Eli Lilly and Company||September 9 2016||Phase 1|
|NCT02659865||Completed||Healthy||Eli Lilly and Company||January 2016||Phase 1|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.